MERCK & CO., INC. (MRK)
Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
📈 **POSITIVE** • Medium confidence analysis (72%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business